New Study published validating further Nevisense indication, Non-melanoma Skin CancerDecember 8, 2020New clinical study supports expansion of indications for Nevisense Study performed in Germany validates the use of Nevisense in non-melanoma skin cancer The study publication is an important milestone in the plan...
SciBase announces changes to the Management teamNovember 4, 2020Linn Olsen, SciBase's head of production and supply chain, has been appointed as a member of the management team. "Our manufacturing of single use electrodes is of strategic importance to the Company an...
Positive step for US reimbursement of NevisenseNovember 2, 2020
STOCKHOLM, SWEDEN, - November 2, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they have been granted a Category III CPT®(CPT III) code from the American Medical Association (AMA) for their Nevisense melanoma detection test.
SciBase releases next generation platform, Nevisense Go.October 30, 2020
STOCKHOLM, SWEDEN, - October 30, 2020 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the release of the first device based on their new platform, Nevisense Go.
SciBase Holding AB announces the outcome of the exercise of warrants of series TO1October 21, 2020
SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the exercise of warrants of series TO1 which were issued in connection with the Company's 19,941,721 units issue on 26 March 2020. The outcome shows that a total of 18,220,264 warrants were exercised for subscription of 18,220,264 new shares in the Company, corresponding to 91.4 percent of the total number of warrants issued in series TO1.
Exercise price for warrants of series TO1 in SciBase Holding AB determined and the subscription period commence on 5 October 2020October 2, 2020
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
- Load more news...